PCBP4 Antibody

What is PCBP4 and why is it important in research?

PCBP4, also known as poly(rC) binding protein 4, is a member of the KH-domain protein subfamily (alpha-CPs) that plays critical roles in post-transcriptional activities through binding to RNA with specificity for C-rich pyrimidine regions. Research significance stems from its induction by the p53 tumor suppressor and its ability to suppress cell proliferation by inducing apoptosis and cell cycle arrest in G(2)-M phase . PCBP4 has been identified as a potential tissue-specific tumor suppressor, with PCBP4-deficient mice showing increased susceptibility to lung adenocarcinoma, lymphoma, and kidney tumors . Understanding PCBP4 function has implications for cancer research, particularly in relation to cisplatin resistance in human maxillary cancers and other head and neck squamous cell carcinomas (HNSCC) .

What species reactivity should I consider when selecting a PCBP4 antibody?

When selecting a PCBP4 antibody, consider the species compatibility with your experimental model. Commercial PCBP4 antibodies typically show reactivity across multiple species. For example, several antibodies demonstrate confirmed reactivity with human, mouse, and rat samples . Some antibodies may also react with additional species such as bovine, dog, and rabbit . Always review the manufacturer's data for specific reactivity information and cross-reference this with your experimental model to ensure appropriate binding in your target species. If working with less common model organisms, validation experiments may be necessary to confirm antibody specificity.

What are the optimal storage conditions for PCBP4 antibodies?

PCBP4 antibodies should generally be stored at -20°C for long-term preservation of activity . Most commercially available PCBP4 antibodies are stable for one year after shipment when stored properly . Some preparations may contain stabilizers such as glycerol (50%) with PBS and 0.02% sodium azide at pH 7.3 . For antibodies supplied in lyophilized form, reconstitution typically involves adding a specified volume (e.g., 100 μL) of sterile PBS to achieve a final concentration of 1 mg/mL . To maintain antibody integrity, avoid repeated freeze-thaw cycles as these can lead to protein denaturation and reduced antibody performance . For working solutions, small aliquots should be prepared and stored separately to minimize freeze-thaw cycles.

How can I optimize Western blot protocols for PCBP4 detection?

For optimal Western blot detection of PCBP4, consider the following methodological approach: First, prepare protein lysates with protease inhibitors to prevent degradation of your target. When loading samples, account for PCBP4's calculated molecular weight of approximately 42 kDa to ensure appropriate gel separation. For primary antibody incubation, begin with manufacturer-recommended dilutions (typically 1:500 to 1:2000) and optimize as needed for your specific sample type.

To maximize specificity, include appropriate positive controls (cell lines known to express PCBP4) and negative controls (PCBP4-deficient samples or blocking peptide competition). For verification of antibody specificity, consider using a blocking peptide designed specifically for your anti-PCBP4 antibody . This can help distinguish between specific and non-specific binding patterns. If experiencing background issues, increase blocking time or adjust detergent concentration in wash buffers. For enhanced sensitivity in detecting low abundance PCBP4, consider signal amplification systems or more sensitive detection reagents.

What are the best approaches for immunoprecipitation of PCBP4-RNA complexes?

For effective immunoprecipitation of PCBP4-RNA complexes, a specialized RNA immunoprecipitation (RIP) protocol tailored to PCBP4's properties is recommended. Based on published methodologies, cross-linking cells with formaldehyde (1% for 10 minutes) helps preserve RNA-protein interactions prior to lysis. Use a lysis buffer containing RNase inhibitors to prevent RNA degradation. For immunoprecipitation, select a validated anti-PCBP4 antibody with established RIP performance and include a normal IgG control to account for non-specific binding.

Evidence from successful PCBP4 RIP experiments has demonstrated that PCBP4 binds to specific mRNAs, including Cdc25A . The association with Cdc25A was verified when it was detected in PCBP4 immunocomplexes but not in normal IgG controls . For RNA extraction and analysis, reverse transcription followed by PCR (RT-PCR) can be used to detect specific target RNAs, as demonstrated in studies with IMC-3PCBP4 cells after cisplatin treatment . For discovery of novel PCBP4-bound transcripts, RNA-seq of immunoprecipitated material has successfully identified potential PCBP4-associated transcripts, which can then be validated by RT-PCR .

What controls should I include when working with PCBP4 antibodies?

Implementing comprehensive controls is essential for robust PCBP4 antibody research. Primary controls should include: (1) Positive controls using cell lines or tissues with known PCBP4 expression; (2) Negative controls using PCBP4-knockout or knockdown samples; (3) Isotype controls utilizing non-specific IgG of the same isotype as your PCBP4 antibody to assess non-specific binding ; and (4) Blocking peptide controls for competitive binding experiments to verify antibody specificity .

For RNA immunoprecipitation experiments, include a non-specific IgG control to distinguish specific PCBP4-RNA interactions from background binding . In functional assays, incorporate both gain-of-function (PCBP4 overexpression) and loss-of-function (PCBP4 knockdown) experimental groups to establish causality in observed phenotypes . When assessing antibody specificity across species, validation in each target species is recommended, even when manufacturers indicate cross-reactivity . Finally, for batch-to-batch variation assessment, maintain a reference sample tested across different antibody lots to ensure consistent performance.

How can PCBP4 antibodies be used to investigate its role in cisplatin resistance?

PCBP4 antibodies can be strategically deployed to elucidate the mechanisms underlying PCBP4's role in cisplatin resistance through several advanced approaches. Immunoblotting with PCBP4 antibodies allows quantification of expression levels before and after cisplatin treatment in sensitive versus resistant cell lines . Studies have demonstrated that PCBP4 levels correlate with cisplatin resistance in human maxillary cancer cells, with suppression of PCBP4 by RNAi reducing cisplatin resistance in IMC-3CR cells and overexpression enhancing resistance in IMC-3 cells .

For mechanistic investigations, co-immunoprecipitation with PCBP4 antibodies can identify protein binding partners involved in cisplatin resistance pathways. Research has revealed that PCBP4 binds to Cdc25A and reduces both its mRNA and protein levels after cisplatin treatment, leading to G2/M arrest . RNA immunoprecipitation followed by RT-PCR or sequencing can identify mRNAs regulated by PCBP4 during cisplatin response . Additionally, chromatin immunoprecipitation (ChIP) may be employed to investigate whether PCBP4 directly regulates transcription of genes involved in cisplatin sensitivity. For translational relevance, immunohistochemistry using PCBP4 antibodies on patient-derived xenografts or tissue microarrays can correlate PCBP4 expression with clinical outcomes in cisplatin-treated patients, potentially establishing PCBP4 as a biomarker for treatment response.

What methodological approaches can determine PCBP4 binding specificity to RNA targets?

Determining PCBP4 binding specificity to RNA targets requires a multi-faceted approach combining in vitro and cellular techniques. RNA electrophoretic mobility shift assay (REMSA) represents a fundamental method for identifying direct RNA-protein interactions. This technique has successfully identified PCBP4 binding sites in transcripts such as the mouse ZFP871 3′ UTR, where specific fragments containing CU-rich elements were recognized by GST-fused PCBP4 protein but not by GST protein alone .

Competition assays provide further validation of binding specificity, as demonstrated when excess unlabeled fragments (e.g., from p21 3′ UTR) decreased the interaction between PCBP4 and 32P-labeled probes . For defining binding motifs, mutational analysis is essential - studies have shown that deletion of a CU-rich element rendered PCBP4 incapable of forming complexes with target fragments . To discover novel PCBP4 RNA targets, RNA immunoprecipitation followed by high-throughput sequencing (RIP-seq) has successfully identified potential PCBP4-associated transcripts in wild-type versus PCBP4-/- mouse embryonic fibroblasts (MEFs) .

For validation of newly identified targets, quantitative RT-PCR can measure relative levels of PCBP4-binding transcripts in wild-type compared to PCBP4-deficient samples . Furthermore, functional assessment of PCBP4-RNA interactions can be performed through mRNA stability assays, which evaluate the half-life of target transcripts in the presence or absence of PCBP4 expression.

How can PCBP4 antibodies be utilized to investigate its tumor suppressor function?

Investigating PCBP4's tumor suppressor function with antibodies requires integrating molecular and animal model approaches. Immunohistochemistry (IHC) with validated PCBP4 antibodies can evaluate expression patterns across normal tissues and tumors from different origins, revealing tissue-specific expression profiles relevant to PCBP4's tumor suppressor role. Studies of PCBP4-deficient mice have demonstrated increased susceptibility to lung adenocarcinoma, lymphoma, and kidney tumors compared to wild-type mice, establishing PCBP4 as a potential tissue-specific tumor suppressor .

For cell cycle analysis, immunoblotting can track PCBP4 expression dynamics during cell cycle progression, while co-immunoprecipitation can identify interactions with cell cycle regulators. Research has shown that PCBP4 binds to Cdc25A and suppresses its expression, resulting in G2/M arrest . Flow cytometry combined with PCBP4 antibody staining can correlate PCBP4 expression with cell cycle phases and apoptotic markers at the single-cell level.

To investigate downstream mechanisms, chromatin immunoprecipitation followed by sequencing (ChIP-seq) may identify genomic binding sites if PCBP4 has direct DNA interactions. For translational research, tissue microarrays from patient cohorts stained with PCBP4 antibodies can correlate expression levels with clinical outcomes and treatment responses, potentially establishing PCBP4 as a prognostic or predictive biomarker. Additionally, evaluating PCBP4 expression in circulating tumor cells might provide insights into its role in metastasis suppression.

How can I troubleshoot non-specific binding when using PCBP4 antibodies?

When encountering non-specific binding with PCBP4 antibodies, implement a systematic troubleshooting approach. First, optimize blocking conditions by extending blocking time (2-3 hours) or evaluating alternative blocking agents (5% BSA, 5% milk, or commercial blocking solutions). For Western blots, ensure membrane washing is thorough with at least three 10-minute TBST washes between antibody incubations. Adjust primary antibody concentration by performing a dilution series (1:500 to 1:5000) to identify optimal signal-to-noise ratio.

Perform blocking peptide competition experiments using a synthetic peptide designed specifically for your anti-PCBP4 antibody . This approach can help distinguish specific from non-specific signals and validate antibody specificity. Evaluate PCBP4 expression in your experimental system using positive control samples with known PCBP4 expression and negative controls (PCBP4 knockdown/knockout samples) to establish expected signal patterns .

For immunoprecipitation applications, pre-clear lysates with protein A/G beads before adding the PCBP4 antibody to reduce non-specific protein binding. Use more stringent wash buffers with increased salt concentration (150 mM to 300 mM NaCl) or detergent (0.1% to 0.5% Triton X-100) for problematic samples. Consider cross-adsorbed secondary antibodies to minimize species cross-reactivity if multiple primary antibodies are being used. Finally, validate results with an alternative PCBP4 antibody targeting a different epitope to confirm specific binding patterns.

What factors affect PCBP4 antibody performance in different applications?

Multiple factors can influence PCBP4 antibody performance across different applications. The antibody class and host species impact specificity and sensitivity - polyclonal antibodies like the rabbit anti-PCBP4 (11046-2-AP) offer high sensitivity but may show more batch-to-batch variation compared to monoclonals. The epitope location within PCBP4 is critical, as antibodies targeting different regions (e.g., middle region ) may perform differently depending on protein conformation and post-translational modifications.

Sample preparation methods significantly impact antibody performance. For Western blotting, complete protein denaturation is essential, while native conditions may be required for immunoprecipitation. Fixation methods for immunohistochemistry or immunocytochemistry (paraformaldehyde vs. methanol) can differentially expose epitopes. Buffer composition, including pH, salt concentration, and detergent type/concentration, directly affects antibody-antigen interactions and should be optimized for each application .

Species cross-reactivity varies between antibodies - some PCBP4 antibodies react with human, mouse, and rat samples , while others show broader reactivity including bovine, dog, and rabbit . This becomes particularly important when working with diverse model systems. Storage conditions and antibody age impact performance, with recommended storage at -20°C and avoiding repeated freeze-thaw cycles . Finally, detection methods (chemiluminescence, fluorescence, colorimetric) offer different sensitivity thresholds and dynamic ranges, necessitating optimization for specific experimental needs.

How can I validate PCBP4 antibody specificity for my experimental system?

Validating PCBP4 antibody specificity requires a multi-pronged approach tailored to your experimental system. Begin with Western blot analysis using positive controls (tissues/cells with known PCBP4 expression) and verify detection at the predicted molecular weight of 42 kDa . Include negative controls through PCBP4 knockdown or knockout samples generated via RNAi or CRISPR-Cas9, which should show corresponding signal reduction . If knockout models are unavailable, compare detection patterns across tissues with varying PCBP4 expression levels.

Peptide competition assays provide direct evidence of specificity by demonstrating signal reduction when the antibody is pre-incubated with its target peptide . For immunoprecipitation validation, perform reciprocal co-IP experiments with antibodies against known PCBP4 interaction partners like Cdc25A . When evaluating novel PCBP4 antibodies, benchmark against previously validated antibodies using the same samples and protocols.

For advanced validation, consider RNA immunoprecipitation followed by RT-PCR to confirm binding to established PCBP4 RNA targets like ZFP871 . Mass spectrometry analysis of immunoprecipitated samples can provide unbiased confirmation of PCBP4 capture. If working with multiple species, verify cross-reactivity experimentally even when manufacturer specifications indicate compatibility . Finally, genetic rescue experiments in PCBP4-deficient systems provide functional validation by demonstrating restoration of PCBP4-dependent phenotypes after reintroduction of the protein.

How can PCBP4 antibodies contribute to cancer research?

PCBP4 antibodies enable multifaceted approaches to cancer research, from basic mechanistic studies to translational applications. For tumorigenesis studies, immunohistochemistry with PCBP4 antibodies can analyze expression patterns across cancer types and stages. Studies have established PCBP4 as a potential tissue-specific tumor suppressor, with PCBP4-deficient mice showing increased susceptibility to lung adenocarcinoma, lymphoma, and kidney tumors . This suggests tissue-specific oncogenic mechanisms that can be further investigated using PCBP4 antibodies.

In drug resistance research, Western blotting and immunofluorescence with PCBP4 antibodies help quantify expression changes in response to chemotherapeutics. Evidence indicates that PCBP4 plays an important role in cisplatin resistance in head and neck squamous cell carcinoma (HNSCC) cells, with suppression of PCBP4 by RNAi reducing cisplatin resistance and overexpression enhancing resistance . For pathway analysis, co-immunoprecipitation with PCBP4 antibodies can identify protein interaction networks in cancer cells, while RNA immunoprecipitation can uncover cancer-relevant mRNA targets of PCBP4.

To investigate metastatic potential, immunofluorescence microscopy using PCBP4 antibodies can track subcellular localization changes during epithelial-mesenchymal transition. For patient stratification, tissue microarray analysis with PCBP4 antibodies may identify expression patterns that correlate with prognosis or treatment response. This approach could establish PCBP4 as a biomarker for personalized cancer therapy, particularly for cisplatin-based regimens in head and neck cancers .

What methodological considerations are important when studying PCBP4 in knockout/knockdown models?

When studying PCBP4 in knockout/knockdown models, several methodological considerations are essential for robust experimental design. For model validation, Western blotting with specific PCBP4 antibodies must confirm complete protein elimination in knockout models or quantify the extent of knockdown . Given that partial knockdown may yield different phenotypes than complete knockout, quantitative assessment of residual PCBP4 expression is critical.

Regarding phenotype characterization, studies with PCBP4-deficient mice have revealed susceptibility to specific tumor types (lung adenocarcinoma, lymphoma, kidney tumors), indicating the need for long-term observation and comprehensive tumor screening . When studying cell cycle regulation, detailed analysis of G2/M transition is particularly relevant, as PCBP4 has been shown to induce G2/M arrest by suppressing Cdc25A expression .

For mechanistic investigations, RNA immunoprecipitation followed by sequencing in wild-type versus PCBP4-deficient models can identify differentially bound transcripts . Target validation requires RT-PCR confirmation of enrichment in anti-PCBP4 immunoprecipitates from wild-type samples compared to knockout models . When analyzing molecular pathways, attention to both direct PCBP4 targets and secondary effects is necessary, as gene expression changes may result from complex regulatory networks rather than direct PCBP4 binding.

To account for potential compensatory mechanisms, expression analysis of other PCBP family members in knockout models is recommended, as functional redundancy may mask phenotypes. Finally, for therapeutic relevance, drug sensitivity assays comparing wild-type and PCBP4-deficient models can identify context-dependent vulnerabilities, particularly with agents targeting cell cycle regulation or DNA damage response pathways .

How can PCBP4 antibodies be used to study its interaction with the p53 pathway?

Investigating PCBP4's interaction with the p53 pathway requires specialized antibody-based approaches tailored to this regulatory axis. Co-immunoprecipitation with PCBP4 antibodies followed by p53 detection (and vice versa) can establish direct protein-protein interactions between PCBP4 and components of the p53 pathway. Proximity ligation assays using paired antibodies against PCBP4 and p53 pathway proteins provide in situ visualization of interactions with subcellular resolution.

For expression correlation analysis, dual immunofluorescence or sequential immunohistochemistry with PCBP4 and p53 antibodies on tissue sections can reveal co-expression patterns. Since PCBP4 is induced by the p53 tumor suppressor , chromatin immunoprecipitation (ChIP) with p53 antibodies can identify direct p53 binding to the PCBP4 promoter, while reporter assays can quantify p53-dependent PCBP4 transcriptional activation.

To assess functional interactions, compare cell cycle profiles and apoptotic responses in wild-type versus PCBP4-knockout cells following p53 activation by DNA damage. RNA immunoprecipitation with PCBP4 antibodies can identify shared mRNA targets of PCBP4 and p53 regulatory networks. For pathway integration analysis, protein and phosphoprotein arrays comparing wild-type and PCBP4-deficient cells after p53 activation can map signaling network alterations.

Finally, for translational relevance, correlative studies of PCBP4 and p53 mutation status in patient samples can determine whether PCBP4 expression or function depends on intact p53 signaling, with potential implications for cancer therapy targeting this axis.